Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + celecoxib + chemotherapy first-line trial in PD-L1-positive, HER2-negative advanced gastric/GEJ adenocarcinoma
ChiCTR2500101406Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab and celecoxib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoints: Objective response rate, COX-2 expression and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
adebrelimabcelecoxib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500101406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101406.